Clinical trials: Treatment Resistant Major Depressive Disorder
Major Depressive Disorder (MDD)
Accelerated TMS for Treatment-Resistant ECT
This study investigates whether an additional treatment using transcranial magnetic stimulation (TMS) can help severely depressed patients who did not respond well to electroconvulsive therapy (ECT).
- Trial name
- A-TREC (NCT07115628)
- Testing
- Transcranial Magnetic Stimulation
- Where
- Belgium
- Volunteers
- 200 people
- Sponsor
- Universitair Ziekenhuis Brussel
Treatment Resistant Depression
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
The goal of this clinical trial is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using Deep Brain Stimulation (DBS) as an adjunctive treatment of non-psychotic…
- Trial name
- TRANSCEND (NCT06423430)
- Testing
- Active-stimulation
- Where
- 26 sites in United States
- Volunteers
- 100 people
- Sponsor
- Abbott Medical Devices
Depressive Disorder, Major
A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder
The primary purpose of this study is to evaluate the efficacy of flexibly dosed esketamine nasal spray compared with quetiapine extended-release (XR), both in combination with a continuing selective serotonin reuptake…
- Trial name
- ESCAPE-TRD (NCT04338321)
- Testing
- Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg
- Where
- 171 sites in Argentina, Austria and 22 more
- Volunteers
- 676 people
- Sponsor
- Janssen-Cilag International NV
Treatment Resistant Depression, Major Depressive Disorder
The UTHealth Ketamine Project
The primary objective of this study is to determine the effectiveness of serial infusions of intravenous (IV) ketamine in adults with treatment resistant depression (TRD).
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Bipolar Disorder
- Trial name
- NCT02882711
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- The University of Texas Health Science Center, Houston
Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD)
Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)
Psilocybin, a serotonin receptor agonist in the brain, significantly and quickly improves depressive symptoms while inducing profound acute subjective effects.
- Trial name
- PSILOTRAZ (NCT07210112)
- Testing
- Psilocybin 25 mg per os, Trazodone 5mg, Trazodone 30 mg
- Where
- France
- Volunteers
- 112 people
- Sponsor
- Centre Hospitalier St Anne
Major Depression
iTBS Versus Standard 10 Hz rTMS for Treatment-Resistant Depression (TRD)
This randomised, parallel-group, non-inferiority trial compared intermittent theta burst stimulation (iTBS, 3-minute sessions) with standard 10 Hz repetitive transcranial magnetic stimulation (rTMS, 37-minute sessions) applied to…
- Trial name
- iTBS-TRD (NCT07852065)
- Testing
- iTBS, rTMS
- Where
- Egypt
- Volunteers
- 182 people
- Sponsor
- Kafrelsheikh University
Suicidal Ideation
Ketamine For Suicidal Ideation
This study will examine the effects of Intravenous (IV) ketamine both in an outpatient population and with subjects on the inpatient unit with suicidal ideation (SI).
- Trial name
- NCT01507181
- Testing
- Ketamine, Midazolam
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- James Murrough
Major Depressive Disorder
Rapid Antidepressant Effects of Leucine
This randomized double-blind placebo-controlled crossover study seeks to evaluate the antidepressant effect of L-leucine, an essential amino acid, in patients with Major Depressive Disorder (MDD).
- Trial name
- NCT03079297
- Testing
- L-Leucine, Maltodextrin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Texas Southwestern Medical Center
Major Depressive Disorder, Treatment Resistant Depression
DBS for TRD With the Medtronic Summit RC+S
Of the estimated 30 million Americans who suffer from Major Depressive Disorder, approximately 10% are considered treatment resistant.
- Trial name
- NCT04106466
- Testing
- Medtronic Summit RC+S DBS system
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Helen Mayberg, MD
Depression, Major Depression
Evaluation of Three Continuation Therapies After ECT Concerning Efficacy and Cognition in Severly Depressed Patients
The purpose of this study is to evaluate three different continuation treatments after acute ECT concerning efficacy and impact on cognition in severly depressed patients.
- Trial name
- EffECT (NCT00437385)
- Testing
- TCAs, SSRIs, NARIs, SNRIs, Lithium, Electroconvulsive therapy, Cognitive behavioral group therapy
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- Charite University, Berlin, Germany
Treatment Resistant Depression
Psilocybin for Treatment-Resistant Depression
The purpose of this study is to see if psilocybin, an investigational drug, is safe and well tolerated. Researchers also want to know if psilocybin can improve symptoms of depression.
- Trial name
- NCT05029466
- Testing
- Psilocybin
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Brain and Cognition Discovery Foundation
Major Depressive Disorder
Treating Refractory Major Depressive Disorder With Repetitive Transcranial Magnetic Stimulation
Studies exploring the efficacy of repetitive transcranial magnetic stimulation (rTMS) as a treatment for refractory major depressive disorder (MDD) have shown significant promise.
- Trial name
- NCT00305045
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- Canada
- Volunteers
- 73 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder, Anhedonia
Psilocybin for Treatment-Resistant Depression
The purpose of this study is to evaluate the efficacy of psilocybin on the symptom of anhedonia in individuals with treatment-resistant major depressive disorder.
- Conditions
- Major Depressive Disorder, Anhedonia, Treatment Resistant Depression
- Trial name
- NCT06230757
- Testing
- Psilocybin 25mg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Colorado, Denver
MDD, Major Depressive Disorder
pBFS Guided rTMS Therapy Over Different Targets for Treatment-Resistant Depression
To explore the effectiveness and safety of rTMS intervention with different targets in the left prefrontal cortex defined using the pBFS method, in adult patients with moderate and severe depressive disorder.
- Conditions
- MDD, Major Depressive Disorder, Treatment Resistant Depression
- Trial name
- NCT05976022
- Testing
- active rTMS
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Changping Laboratory
Depression, Depressive Disorder
Buprenorphine for Treatment Resistant Depression
The purpose of this study is to compare the safety and efficacy of buprenorphine with placebo for adults with treatment resistant depression (TRD).
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- BUP-TRD (NCT01407575)
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Pittsburgh
Major Depressive Disorder, Major Depressive Episode
Glabellar Botulinum Toxin Injections for the Treatment of Geriatric Depression
The effectiveness of glabellar injection of botulinum toxin type A (BTA) in treating depression has not yet been investigated in elderly patients.
- Conditions
- Major Depressive Disorder, Major Depressive Episode, Treatment Resistant Depression
- Trial name
- BOTDEP (NCT03833063)
- Testing
- botulinum toxin A
- Sponsor
- Helse Stavanger HF
Major Depressive Disorder
Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder
The primary hypothesis is that compared to placebo, 10g of daily creatine monohydrate for eight weeks will be associated with significant increases in frontal lobe phosphocreatine and beta-nucleoside triphosphate (β-NTP)…
- Trial name
- NCT02134808
- Testing
- Creatine
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Perry Renshaw
Major Depressive Disorder, MDD
A Non Interventional Study to Investigating the Ratio of Mis-diagnosed Bipolar Symptoms in Patient With Major Depressive Disorder (MDD)
The study will only detect hypomanic symptoms in treatment resistant MDD patients by mean of HCL-32 administration. Further re-evaluation of MDD diagnosis is not a direct aim of the study.
- Trial name
- Improve (NCT01344733)
- Where
- 29 sites in Italy
- Volunteers
- 660 people
- Sponsor
- AstraZeneca
Treatment-resistant Depression
A Trial of GH001 in Patients With Treatment-resistant Depression
The aim of this randomized, double-blind, placebo-controlled, phase 2b clinical trial is to investigate the safety and efficacy of GH001 (containing mebufotenin [5-methoxy-N,N-dimethyltryptamine; 5-MeO-DMT]) in patients with…
- Trial name
- NCT05800860
- Testing
- GH001
- Where
- 11 sites in Czechia, Germany and 4 more
- Volunteers
- 81 people
- Sponsor
- GH Research Ireland Limited
Major Depressive Disorder
Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression
The purpose of the study is to determine the efficacy, safety and pharmacokinetics of inhaled Esketamine in participants with treatment-resistant depression (TRD) in the course of Major Depressive Disorder (MDD).
- Trial name
- NCT03965858
- Testing
- Esketamine DPI - low dose, Esketamine DPI - medium dose, Esketamine DPI - high dose
- Where
- 12 sites in Poland
- Volunteers
- 88 people
- Sponsor
- Celon Pharma SA